Gilead Sciences Reports Phase 3 Results for Seladelpar in NASH

Gilead Sciences today announced results from the Phase 3 RESPONSE trial evaluating seladelpar in patients with nonalcoholic steatohepatitis (NASH) and liver fibrosis. The trial demonstrated significant improvements in liver histology, including reductions in NASH activity and fibrosis scores, compared to placebo at week 52.